MATINAS BIOPHARMA HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations of 238.00 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations · last filed 2025-04-15
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for the quarter ending 2023-12-31 was 0.00 shares.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for the quarter ending 2023-09-30 was 0.00 shares.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for the quarter ending 2021-12-31 was -19.98K shares, a 101.34% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for the quarter ending 2020-12-31 was 1.49M shares.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for fiscal 2023 was 238.00K shares, a 67900.00% increase from fiscal 2022.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for fiscal 2022 was 350.00 shares, a 1650.00% increase from fiscal 2021.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for fiscal 2021 was 20.00 shares, a 100.00% decline from fiscal 2020.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for fiscal 2020 was 1.49M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | 0.00 shares derived: sum of 2 quarters · filed 2025-04-15 | 238.00K shares 10-K · filed 2025-04-15 | 238.00 shares 10-K · filed 2024-03-27 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 238.00K shares 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | 238.00K shares 10-Q · filed 2023-08-09 | ||||
| 2022-12-31 | 350.00 shares 10-K · filed 2024-03-27 | ||||
| 2021-12-31 | -19.98K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 20.00 shares 10-K · filed 2023-03-15 | 20.00K shares 10-K · filed 2022-03-08 | ||
| 2021-09-30 | 20.00K shares 10-Q · filed 2021-11-08 | ||||
| 2020-12-31 | 1.49M shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | 1.49M shares derived: sum of 2 quarters · filed 2022-03-11 | 1.49M shares 10-K/A · filed 2022-03-11 | ||
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | 1.49K shares 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | 1.49K shares 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |